Is Capivasertib a targeted drug or an endocrine drug?

Capivasertib (Capivasertib) is strictly a targeted drug, not an endocrine therapy drug in the traditional sense. It is a highly selective AKT inhibitor that specifically targets AKT kinase in the PI3K/AKT/mTOR signaling pathway. This pathway is widely involved in the proliferation, survival and resistance to treatment of tumor cells. In many solid tumors, such as breast cancer, prostate cancer, ovarian cancer, etc., abnormal activation of the AKT pathway is closely related to tumor development. Especially in hormone receptor-positive breast cancer, activation of AKT is often an important mechanism leading to the failure of endocrine therapy.

Although capositinib is currently mainly used in combination with endocrine drugs such as fulvestrant for the treatment of HR+/HER2- breast cancerHR+/HER2- breast cancer, its core mechanism of action is to target the inhibition of signaling pathways rather than regulating hormone levels or blocking hormone receptors, which is essentially different from endocrine drugs such as tamoxifen or aromatase inhibitors. Its main function is to break the "barrier" of endocrine therapy resistance and restore the sensitivity of cancer cells to hormone therapy by inhibiting the AKT pathway, thereby improving the therapeutic effect. Therefore, in treatment strategies, capositinib is often used as an enhanced treatment, in conjunction with endocrine drugs, rather than as a substitute.

It is worth mentioning that the biggest advantages of targeted drugs are precision and specificity of molecular mechanisms. Capacetinib controls tumor progression through targeted intervention on AKT kinase, which not only has important application potential in the field of breast cancer, but may also be expanded to more malignant tumors with abnormalities in the PI3K-AKT pathway. In the future, as the trend of personalized treatment advances, targeted therapy will complement endocrine therapy and immunotherapy, and capositinib will play a key "signaling pathway regulator" role. For clinicians, only by rationally evaluating patients' molecular markers can the therapeutic value of such targeted drugs be truly unleashed.

Reference materials:https://www.drugs.com/mtm/capivasertib.html